Profile data is unavailable for this security.
About the company
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
- Revenue in USD (TTM)0.00
- Net income in USD-56.83m
- Incorporated2021
- Employees51.00
- LocationRezolute Inc275 Shoreline Drive, Suite 500REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 206-4507
- Fax+1 (302) 636-5454
- Websitehttps://www.rezolutebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gritstone bio Inc | 16.35m | -138.49m | 108.20m | 231.00 | -- | 1.90 | -- | 6.62 | -1.55 | -1.55 | 0.1827 | 0.5313 | 0.0781 | -- | 36.53 | 70,761.91 | -66.18 | -48.08 | -77.72 | -55.18 | -- | -- | -847.24 | -573.71 | -- | -- | 0.4364 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Allakos Inc | 0.00 | -185.70m | 108.47m | 131.00 | -- | 0.6368 | -- | -- | -2.14 | -2.14 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -58.95 | -42.71 | -65.92 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Sangamo Therapeutics Inc | 176.23m | -257.83m | 112.03m | 405.00 | -- | 1.16 | -- | 0.6357 | -1.46 | -1.46 | 1.01 | 0.4653 | 0.4843 | -- | 76.61 | 435,140.80 | -70.85 | -26.09 | -90.72 | -31.04 | -- | -- | -146.30 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -68.96m | 112.15m | 63.00 | -- | 0.4969 | -- | -- | -1.44 | -1.44 | 0.00 | 4.39 | 0.00 | -- | -- | 0.00 | -26.40 | -21.16 | -27.72 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Relmada Therapeutics Inc | 0.00 | -98.79m | 115.27m | 20.00 | -- | 1.35 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Rezolute Inc | 0.00 | -56.83m | 115.57m | 51.00 | -- | 1.24 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| OptiNose Inc | 70.99m | -35.48m | 116.43m | 132.00 | -- | -- | -- | 1.64 | -0.3162 | -0.3162 | 0.6329 | -0.7705 | 0.5635 | 0.9869 | 2.64 | 537,780.30 | -28.17 | -48.25 | -- | -98.95 | 87.84 | 86.96 | -49.99 | -131.66 | 0.5511 | -1.79 | 2.99 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 117.32m | 56.00 | -- | 1.38 | -- | 199.52 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Leap Therapeutics Inc | 0.00 | -81.41m | 117.47m | 54.00 | -- | 1.31 | -- | -- | -5.11 | -5.11 | 0.00 | 2.35 | 0.00 | -- | -- | 0.00 | -113.72 | -80.06 | -136.52 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 118.28m | 8.00 | -- | 3.27 | -- | 19.71 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 118.86m | 93.00 | -- | 2.87 | -- | 24.07 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.64m | 119.89m | 69.00 | -- | 0.9847 | -- | -- | -2.13 | -2.13 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -48.43 | -- | -51.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 120.06m | 168.00 | -- | 0.7928 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Inotiv Inc | 585.17m | -33.21m | 121.47m | 1.96k | -- | 0.4779 | 5.55 | 0.2076 | -1.29 | -1.29 | 22.73 | 9.85 | 0.6858 | 6.46 | 7.12 | 299,320.70 | -3.96 | -23.84 | -4.62 | -29.26 | 30.29 | 29.31 | -5.78 | -33.24 | 1.28 | 0.1431 | 0.5988 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.33m | 123.48m | 22.00 | -- | 1.28 | -- | -- | -0.255 | -0.255 | 0.00 | 0.533 | 0.00 | -- | -- | 0.00 | -36.52 | -30.26 | -38.61 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Immunic Inc | 0.00 | -93.61m | 124.31m | 77.00 | -- | 2.15 | -- | -- | -2.11 | -2.11 | 0.00 | 0.6404 | 0.00 | -- | -- | 0.00 | -102.84 | -72.09 | -129.79 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
Data as of May 08 2024. Currency figures normalised to Rezolute Inc's reporting currency: US Dollar USD
50.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 18 Mar 2024 | 6.61m | 16.68% |
| Stonepine Capital Management LLCas of 31 Dec 2023 | 2.77m | 6.99% |
| First Manhattan Co LLCas of 31 Dec 2023 | 2.68m | 6.77% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 1.54m | 3.88% |
| Blackstone Alternative Asset Management LPas of 31 Dec 2023 | 1.54m | 3.88% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.40m | 3.52% |
| Caxton Corp.as of 31 Dec 2023 | 1.32m | 3.33% |
| Sphera Funds Management Ltd.as of 31 Dec 2023 | 996.71k | 2.52% |
| Adage Capital Management LPas of 31 Dec 2023 | 631.69k | 1.59% |
| UBS O'Connor LLCas of 31 Dec 2023 | 601.26k | 1.52% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
